BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17323186)

  • 1. Chemopreventive effect of celecoxib in gastric cancer.
    Futagami S; Suzuki K; Hiratsuka T; Shindo T; Hamamoto T; Ueki N; Kusunoki M; Miyake K; Gudis K; Tsukui T; Sakamoto C
    Inflammopharmacology; 2007 Feb; 15(1):1-4. PubMed ID: 17323186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats].
    Tang BD; Zeng ZR; Hu PJ
    Ai Zheng; 2006 Oct; 25(10):1205-9. PubMed ID: 17059761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication.
    Hung KH; Yang HB; Cheng HC; Wu JJ; Sheu BS
    J Gastroenterol Hepatol; 2010 Jan; 25(1):48-53. PubMed ID: 19793174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Celecoxib induces apoptosis and inhibits angiogenesis in gastric cancer].
    Ran JT; Zhou YN; Tang CW; Lu JR; Wu J; Lu H; Yang GD
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):448-51. PubMed ID: 19024521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Questions #6. Does celecoxib increase cardiovascular risk?
    Mayer BJ; Lamfers R; Feldstein DA
    WMJ; 2005 Nov; 104(8):15-6. PubMed ID: 16425910
    [No Abstract]   [Full Text] [Related]  

  • 6. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model.
    Nam KT; Hahm KB; Oh SY; Yeo M; Han SU; Ahn B; Kim YB; Kang JS; Jang DD; Yang KH; Kim DY
    Clin Cancer Res; 2004 Dec; 10(23):8105-13. PubMed ID: 15585646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Celecoxib and cardiovascular risks.
    Brophy JM
    Expert Opin Drug Saf; 2005 Nov; 4(6):1005-15. PubMed ID: 16255660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
    Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
    Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.
    Jacob S; Laury-Kleintop L; Lanza-Jacoby S
    J Surg Res; 2008 May; 146(1):135-42. PubMed ID: 17950326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Short-term preoperative treatment of celecoxib, a selective cyclooxygenase-2 inhibitor, on E-cadherin expression in gastric carcinoma tissues].
    Ran JT; Zhou YN; Tang CW; Li HH; Li XW; Lu H
    Ai Zheng; 2009 Apr; 28(4):361-5. PubMed ID: 19622294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia After H. pylori eradication.
    Sheu BS; Tsai YC; Wu CT; Chang WL; Cheng HC; Yang HB
    Helicobacter; 2013 Apr; 18(2):117-23. PubMed ID: 23067366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of antinociceptive efficacy and gastroprotection between celecoxib and diclofenac plus misoprostol in rats.
    Reyes-García G; Déciga-Campos M; Medina-Santillan R; Granados-Soto V
    Proc West Pharmacol Soc; 2007; 50():69-71. PubMed ID: 18605234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.
    Antoniou K; Malamas M; Drosos AA
    Expert Opin Pharmacother; 2007 Aug; 8(11):1719-32. PubMed ID: 17685888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks and benefits of celecoxib to prevent recurrent adenomas.
    Psaty BM; Potter JD
    N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408
    [No Abstract]   [Full Text] [Related]  

  • 15. Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.
    Knight S; Johns EJ
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):11-6. PubMed ID: 18047621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.
    Noguchi M; Kimoto A; Kobayashi S; Yoshino T; Miyata K; Sasamata M
    Eur J Pharmacol; 2005 Apr; 513(3):229-35. PubMed ID: 15862805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth.
    Bozzo F; Bassignana A; Lazzarato L; Boschi D; Gasco A; Bocca C; Miglietta A
    Chem Biol Interact; 2009 Dec; 182(2-3):183-90. PubMed ID: 19682443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of celecoxib on normal and acid-challenged gastric mucosa.
    Dutta N; Sarotra P; Gupta S; Aggarwal R; Agnihotri N
    Exp Toxicol Pathol; 2009 Jul; 61(4):353-61. PubMed ID: 19041231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication.
    Yang HB; Cheng HC; Sheu BS; Hung KH; Liou MF; Wu JJ
    Aliment Pharmacol Ther; 2007 Feb; 25(4):455-61. PubMed ID: 17270001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP.
    He Q; Luo X; Jin W; Huang Y; Reddy MV; Reddy EP; Sheikh MS
    Oncogene; 2008 Apr; 27(18):2656-60. PubMed ID: 17968315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.